Aberrant expression of PD-1 on B cells and its association with the clinical parameters of systemic lupus erythematosus

Yang Lu  
Affiliated Hospital of Bengbu Medical College

Qingqing Zhu  
Affiliated Hospital of Bengbu Medical College

Yun Li  
Affiliated Hospital of Bengbu Medical College

Qiyi Wang  
Bengbu Medical College

Chao Jiang  
Affiliated Hospital of Bengbu Medical College

Zhijun Li  
Affiliated Hospital of Bengbu Medical College

Hongtao Wang  
Affiliated Hospital of Bengbu Medical College

Yan Wang  
Affiliated Hospital of Bengbu Medical College

Wei Zhang  
Bengbu Medical College

Yuanyuan Wang  
Bengbu Medical College

Changhao Xie  (✉ uglboy2002@126.com )  
the first affiliated hospital of Bengbu medical college  https://orcid.org/0000-0001-5039-5969

Research article

Keywords: PD-1; B cells; subpopulation; abnormal; systemic lupus erythematosus

Posted Date: February 12th, 2020

DOI: https://doi.org/10.21203/rs.2.17942/v2

License: ☉ ☀ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Programmed death 1 (PD-1) is an immunoregulatory receptor that inhibits T cell activation and proliferation upon binding to its cognate ligand (PD-L1). However, the role of the PD-1/PD-L1 axis in B cell function, especially in inflammatory and autoimmune disorders, is less clear. The aim of this study was to analyze the PD-1 expression patterns on multiple B cell subpopulations isolated from systemic lupus erythematosus (SLE) patients, and determine their clinical relevance. Results: The frequency of B cells increased significantly in patients with active SLE compared with healthy controls and patients with inactive SLE. In particular, the frequencies of the IgD CD27 and IgD CD27high (plasmablast cells) subpopulations were significantly higher in the patients compared to healthy individuals. Interestingly, the patients with active SLE harbored an increased proportion of the PD-1+ B cells, which correlated significantly with the disease severity (SLEDAI scores), incidence of lupus nephritis, and the circulating levels of autoantibodies and complement factors. Furthermore, the primary PD-1+ B cells isolated from the peripheral blood of SLE patients proliferated faster and secreted more anti-dsDNA antibodies and immunoglobulins in vitro compared to the PD-1+/− B cells from healthy controls. Conclusions: PD-1 is overexpressed on all B cell subpopulations of SLE patients and associated with disease progression.

Background

Systemic lupus erythematosus (SLE) is a chronic inflammatory condition that affects the connective tissues of multiple organs, and is the result of excessive autoimmune response. It manifests as fatigue, fever, joint and muscular pain, and the characteristic “buttery rash” across the cheeks and nose. Although the exact etiological and pathological mechanisms underlying SLE are unknown, auto-reactive T and B cells have been frequently implicated.

The activation of T cells is primarily regulated by the programmed death 1 (PD-1) receptor and its ligands PD-L1 and PD-L2, which form an immune checkpoint that is essential for maintaining tolerance to self-antigens and preventing autoimmune disorders. Furthermore, the PD-1/PD-L axis is often disrupted in animal models simulating human autoimmune diseases, and directly affects immune activation and homeostasis. Interestingly, blocking either PD-1 or PD-L1 in a murine model of lupus-like nephritis significantly alleviated tissue inflammation and other symptoms by inhibiting the autoreactive T cells and concomitantly increasing the proportion of the immunosuppressive CD8+ subset. In addition, anti-PD-L1 immunoglobulin improved the survival of these mice by delaying proteinuria onset. However, the exact pathological relevance of the PD-1/PD-L1 axis in human SLE remains to be elucidated.

Studies show that antigen-primed SLE patients that are recalcitrant to immunosuppressive therapy harbor an expanded IgD CD27+ class-switched memory B cell population, which can be attributed to aberrant B-cell receptor (BCR) editing and somatic hypermutation in the peripheral memory B cells. These abnormal memory B cells significantly increase the risk of autoimmune responses on account of their lower antigen-dependent activation thresholds, as well as antigen-independent activation through the B-cell-activating factor, Toll-like receptor agonists or cytokines. The IgD CD27+ memory B cell subset is also enriched in the SLE patients, and correlates with increased disease severity and renal involvement. Interestingly, IgD CD27+ B cells harboring mutated BCRs have been detected in the peripheral blood and lymphoid tissues of healthy donors as well. However, the functional relationship between the PD-1/PD-L1 axis and memory B cell activity in SLE is not clear. To this end, we analyzed the expression patterns of PD-1 on different B cell populations in SLE patients, and determined their correlation with clinical indices.

Methods

Patients

Seventy-four Asian-origin SLE patients diagnosed as per the 1997 American College of Rheumatology revised criteria, and 54 matched healthy controls were enrolled at the Department of Rheumatology of the First Affiliated Hospital of Bengbu Medical College, China. The medical records of all participants were screened for age, gender, blood cell counts, 24-h urinary protein secretion, circulating levels of anti-dsDNA, anti-nucleosome, anti-Smith (anti-Sm), anti-Sjogren syndrome A (anti-SSA) and anti-Sjogren syndrome B (anti-SSB) antibodies, complement component 3 (C3) and C4, IgG, IgM and IgA, and the erythrocyte sedimentation rates (ESR). The disease activity was scored according to the SLE Disease Activity Index (SLEDAI) and the patients were classified into the inactive (SLEDAI <10) and active (SLEDAI ≥10) groups.

Flow cytometry

Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized whole blood (3 mL) of SLE patients and controls using Ficoll-Hypaque density gradient centrifugation, and stained with FITC-anti-CD3, PE-anti-CD3, APC-anti-CD3, APC-Cy7-anti-CD19, FITC-anti-IgD, APC-anti-CD27, and PE-anti-PD-1 antibodies (all from Biolegend, 9727 Pacific Heights Blvd, San Diego, CA 92121, USA, 1:1000) as appropriate. The cells were acquired in a FACS Verse flow cytometer (BD Bioscience, San Jose, CA 95131, USA) and analyzed using the Flowjo software (Version X; Tree Star, Ashland, OR, USA). Furthermore, PBMCs isolated from 20 mL fasting blood samples were stained with the anti-CD19 and anti-PD-1 antibodies, and the CD19+PD-1+ and CD19+PD-1- populations were sorted using FACS Aria II (BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, 877.232.8995, USA). After establishing >95% purity, the PD-1+ and PD-1− B cells were stained with 5M CFSE (Molecular Probes, Waltham, MA, USA) in phosphate-buffered saline/0.1% bovine serum albumin at 37°C for 10 min to determine their viability. The cells were seeded in RPMI 1640 medium supplemented with 10% fetal calf serum and 10 ng/mL IL-2 and IL-10 (PeproTech Rocky Hill, NJ, USA) at the density of 2×10^5/well, and cultured for 7 days in the presence of 2.5 μg/mL CpG2006 oligonucleotide (Invivogen, San Diego, CA, USA) and/or 2.5 μg/mL goat F(ab)2 anti-human IgM. The medium was changed every 2 days, and the ensuing clones were then stained with anti-PD-1 antibody for flow cytometry analysis.

Enzyme linked immunosorbent assay (ELISA)
The levels of anti-dsDNA antibody and IgG in the supernatants (see above) were analyzed on days 1, 3, 5 and 7 of culture by ELISA (Biorbyt, San Francisco, CA, USA).

Statistical analysis

All data were presented as mean ± standard deviation, and compared by one-way analysis of variance or two-tailed Student t test as appropriate. The correlation between two variables was analyzed by Spearman or Pearson correlation coefficient. P values < 0.05 were considered statistically significant. All data were analyzed using SPSS 16.0 (IBM, Armonk, NY, USA).

Results

The B cell subpopulations are skewed in SLE

As shown in Table 1, the SLE patients and controls did not differ significantly in terms of age and gender, and the patients displayed the clinicopathological features of SLE. The relative proportion of CD19+ B cells was significantly higher in the SLE patients compared to controls (P < 0.05), and slightly higher among those with active as opposed to inactive disease (Fig 1A-B). Furthermore, the SLE patients also harbored significantly expanded CD19+ IgD- CD27+ (double negative or DN) and CD19+ IgD+ CD27+ plasmablast cell (PC) populations compared to the healthy controls (Fig 1C-D). Interestingly, while the overall high B cell frequency did not affect the clinical symptoms or circulating autoantibody levels in the patients (data not shown), it correlated positively with the SLEDAI score and 24-h urinary protein levels, and negatively with C3 levels (Fig 1E). In contrast, a positive correlation was seen between the frequency of PC and the IgM and C3 levels. Furthermore, the CD27+ class-switched memory (SM) and CD27- non-switched memory (NSM) B cells respectively correlated with higher SLEDAI scores and 24h urinary protein levels. Both populations showed a significant positive correlation with IgG levels and a negative correlation with that of IgM. The naïve B cells on the other hand were negatively associated with both SLEDAI and IgG levels (Table 2). Patients exhibiting the malar rash and positive for anti-histones and anti-SSA52 antibodies showed an increased proportion of both SM and naïve B cells whereas the presence of only anti-SSB and anti-SSA52 antibodies correlated with an increase in the NSM population (Table 3). The other B cell subsets however did not show any significant association with the clinical and biochemical indices of SLE (Table 3).

B cells of SLE patients express PD-1 and correlate with the clinical progression

The frequency of the PD-1+ B cells was significantly higher in the SLE patients compared to the healthy controls, as well as in the patients with active as opposed to inactive disease (Fig. 2A-B). Furthermore, PD-1 was overexpressed on all B cell subpopulations in SLE patients (Fig. 2C-D). The expanded PD-1+ B cell population in the patients was associated with increased SLEDAI scores, as well as higher 24-h urinary protein levels. In addition, the serum levels of IgG and IgM respectively correlated positively and negatively with these cells (Fig. 2E). The frequency of PD-1+ B cells was significantly higher in patients positive for the anti-dsDNA (P = 0.040), anti-histone (P = 0.025) and anti-SSA52 (P = 0.048) antibodies, and those presenting lupus nephritis (P < 0.001) and oral ulcers (P = 0.05). In contrast, no significant association was observed between PD-1+ B cells and the hematological manifestations of SLE, arthritis or serositis (Table 4). We also analyzed the clinical significance of the distinct B-cell subsets expressing PD-1 (Table 5), and found that the PD-1+ PCs correlated positively associated with SLEDAI scores, 24-h urinary protein secretion and IgG levels, PD-1+ SM B cells with SLEDAI scores and 24-h urinary protein levels, and the PD-1+ NSM and naïve B cells with only IgG levels (Fig. 2F). Based on these findings, we surmised that the PD-1-expressing B cells are the effectors of SLE progression.

PD-1+ B cells from SLE patients secrete large amounts of autoantibodies

To validate the above hypothesis, we isolated primary PD-1+ and PD-1- B cells from the SLE patients and controls, and cultured them in vitro in the presence of CpG DNA. As shown in Fig. 3A-B, the PD-1+ B cells from SLE patients were highly responsive to CpG DNA stimulation and showed markedly higher proliferation rates compared to the PD-1+ B cells from healthy controls, as well as the PD-1+ B cells isolated from SLE patients or controls. In addition, the SLE PD-1+ B cells secreted significantly higher levels of anti-dsDNA antibodies (P < 0.01, P < 0.001; Fig. 3C) and IgG (P = 0.0261; Fig. 3D) compared to the control PD-1+ and SLE/control PD-1- cells. Thus, the auto-reactive PD-1+ B cells likely mediate the pathological changes in SLE by secreting large amounts of autoantibodies.

Discussion

Activated B cells are the key effectors of SLE development and progression, and induce the pathological changes by producing autoantibodies and inflammatory cytokines. In addition, they also activate specific T cells by functioning as antigen presenting cells. Previous studies have reported significant changes in the proportion of different B-cell subsets in SLE patients. Consistent with this, we detected a significant increase in the frequency of different B cell phenotypes in SLE patients, and particularly of the SM and DN cells among those with active disease. A previous study reported increased frequency of DN B cells in SLE patients, which correlated to higher SLEDAI scores and elevated anti-dsDNA and anti-Sm antibodies in circulation. Other studies have identified an aberrant CD19+ IgD- CD27- CXCR5+ B cell subset in SLE patients, which is closely associated with the inflammatory changes characteristic of the disease. In agreement with our findings, Kubo et al detected increased proportion of both the DN and PC subsets in SLE patients compared to the healthy controls. In our study however, only the expanded PD-1+ CD19+ sub-population was associated with increased disease severity, overproduction of autoantibodies and the clinical manifestations, indicating that it plays a key role in SLE progression as opposed to the other B cell subsets.
PD-1/PD-L1 binding suppresses T-cell activation and expansion by inhibiting TCR-dependent signaling\(^7,37\). Not surprisingly therefore, the immunosuppressive PD-1-expressing CD8\(^+\) T cells are exhausted during chronic viral infection\(^38,39\). In stark contrast, clonal expansion of antigen-primed PD-1\(^+\)CD8\(^+\) T effector cells has been observed during chronic inflammation\(^40\), and the PD-1\(^+\) CD4\(^+\) T cell population in mice with lupus-like symptoms secrete excessive amounts of interferon (IFN)\(^-\)γ\(^17\). Consistent with this, PD-1\(^+\) CD4\(^+\) T cells isolated from the blood of SLE patients activated B cells in vitro in the presence of interleukin (IL)-10\(^41\). These findings point to an immunogenic role of PD-1 in chronic inflammatory and autoimmune disorders, which is contradictory to its inhibitory effect on the phagocytic activity of tumor-associated macrophages\(^42\). This strongly indicates the existence of multiple functionally distinct immune cell subsets with differential PD-1 expression. Indeed, Thibult et al identified several B-cell subpopulations with divergent PD-1 levels\(^43\), and found that inhibiting PD-1 signaling activated B cells, promoted their clonal expansion and increased the production of effector cytokines\(^43\). Similarly, PD-1 blockade in Streptococcus pneumoniae capsule-primed B cells significantly enhanced proliferation and immunoglobulin production\(^44\).

Although the above findings clearly implicate PD-1 signaling in B cell survival and function, its potential role in SLE is largely unknown. We detected a substantial CD19\(^+\) PD-1\(^+\) B cell population in the SLE patients, which correlated significantly with disease severity, inflammation and high levels of circulating autoantibodies. In vitro expansion of these cells was also associated with increased proliferation and secretion of IgG and anti-dsDNA antibodies. Contrary to a previous study that reported an inhibitory effect of PD-1 on B cell activation\(^45\), our findings indicate that an aberrant PD-1-expressing B cell subset is the likely autoimmune effector in SLE. It is possible that the abnormal activation of these auto-reactive B cells is due to certain SLE-related pathological factors rather than PD-1, wherein the latter is merely a marker of this population and not functionally relevant. Furthermore, PD-1 might be upregulated on the B cells following their activation and in fact exert an inhibitory effect via negative feedback. A previous study showed elevated PD-1 on the IgM\(^+\) IgD\(^+\) CD27\(^+\) memory B cells as opposed to the naïve and SM populations\(^43\). Although all B-cell subpopulations in the SLE patients of our cohort overexpressed PD-1, only some of these subsets were associated with autoantibody production and clinical parameters. The mechanism underlying PD-1 overexpression in the autoreactive B cells, the functional importance of specific PD-1\(^+\) B cell subsets in SLE, and the potential interactions between the PD-1\(^+\) B cells and T cells remain to be elucidated.

Conclusions

To summarize, the B cell phenotypes and PD-1 expression pattern are skewed in SLE patients, and the expanded CD19\(^+\)PD-1\(^+\) population is primarily associated with the pathological changes in SLE.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| C3           | complement 3 |
| C4           | complement 4 |
| dsDNA        | double-stranded DNA |
| IgA          | immunoglobulin A |
| IgG          | immunoglobulin G |
| LN           | lupus nephritis |
| N            | naïve |
| NSM          | non-switched memory |
| PC           | plasmablast cells |
| PD-1         | programmed death 1 |
| PD-L1        | programmed death ligand 1 |
| Sm           | smith |
| SSA          | Sjögren syndrome antigen A |
| SLE          | systemic lupus erythematosus |
| SLEDAI       | systemic lupus erythematosus disease activity index |
| SM           | switched memory |
| SSB          | Sjögren syndrome antigen B |
| U1snRNP      | U1 small nuclear ribonucleoprotein |

Declarations

Ethics approval and consent to participate

All participants provided informed written consent. This study was approved by the institutional review board of the First Affiliated Hospital of Bengbu Medical College.
Consent for publication

The consent to publish has been acquired from each patient at the beginning of study.

Availability of data and material

The data are owned by Changhao Xie. All data are available from the corresponding author on reasonable request.

Competing interests

The authors declare no financial interests.

Funding

This study was supported by the Anhui Provincial Natural Science Foundation (1608085MH215), and the Key Project of Natural Science Foundation Universities Anhui Province (KJ2019A0319, KJ2016A475), which helped with the design of the experiment and paper writing; the Key Program of Anhui Educational Committee (KJ2018A0228), and the Natural Science Foundation of Universities in Anhui Province (KJ2013B139), which helped with data collection; the Postgraduate Science and Technology Innovation Project of Bengbu Medical College in Anhui Province (Byyczx1609 and Byyczx1728), and the Undergraduate Training Programs for Innovation and Entrepreneurship in Anhui Province (201810367017, 201810367056), which helped with flow cytometry data analysis.

Authors' contributions

CX, Yuan Wang conceived and designed the work. QW, CJ contribute to collect peripheral blood samples of subjects. YLu, QZ and YLi performed the experiments. QZ, Yan Wang, WZ analyzed data and statistical analysis. YLu and CX drafted the manuscript. ZL and HW critically revised the manuscript for important intellectual content.

Acknowledgements

The authors wish to thank Baiqing Li and Jie Tang for their direction the experiment.

References

1. Lisnevskaiia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384(9957): 1878-88.
2. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis research & therapy 2009; 11(5): 247.
3. Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis research & therapy 2011; 13(5): 243.
4. Suarez-Fueyo A, Bradley SJ, Tsokos GC. T cells in Systemic Lupus Erythematosus. Current opinion in immunology 2016; 43: 32-8.
5. Schrezenmeier E, Weissenberg SY, Stefanski AL, et al. Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. Current opinion in rheumatology 2019; 31(2): 175-84.
6. Wang LL, Li ZH, Hu XH, Muyayalo KP, Zhang YH, Liao AH. The roles of the PD-1/PD-L1 pathway at immunologically privileged sites. American journal of reproductive immunology 2017; 78(2).
7. Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity 2018; 48(3): 434-52.
8. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nature reviews Immunology 2018; 18(3): 153-67.
9. Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nature communications 2015; 6: 5997.
10. Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. Journal of immunology 2008; 181(4): 2513-21.
11. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11(2): 141-51.
12. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291(5502): 319-22.
13. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. The Journal of experimental medicine 2003; 198(1): 63-9.
14. Boussioutis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. The New England journal of medicine 2016; 375(18): 1767-78.
15. Zhang Q, Vignali DA. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity 2016; 44(5): 1034-51.
16. Sage PT, Schildberg FA, Sobel RA, Kuchroo VK, Freeman GJ, Sharpe AH. Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function. Journal of immunology 2018; 200(8): 2592-602.
17. Kasagi S, Kawano S, Okazaki T, et al. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. Journal of immunology 2010; 184(5): 2337-47.
18. Wong M, La Cava A, Singh RP, Hahn BH. Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. Journal of immunology 2010; 185(11): 6563-71.
19. Wong M, La Cava A, Hahn BH. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. *Journal of immunology* 2013; **190**(11): 5402-10.

20. Zhou H, Xiong L, Wang Y, et al. Treatment of murine lupus with PD-Lig. *Clinical immunology* 2016; **162**: 1-8.

21. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. *Journal of immunology* 2000; **165**(10): 5970-9.

22. Domer T, Foster SJ, Famer NL, Lipsky PE. Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. *The Journal of clinical investigation* 1998; **102**(4): 688-94.

23. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. *Annals of the rheumatic diseases* 2008; **67 Suppl 3**: iii83-6.

24. Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. *Arthritis and rheumatism* 2008; **58**(6): 1762-73.

25. Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. *Journal of immunology* 2007; **178**(10): 6624-33.

26. Ma CS, Pittaluga S, Avery DT, et al. Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. *The Journal of clinical investigation* 2006; **116**(2): 322-33.

27. Fecteau JF, Cote G, Neron S. A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. *Journal of immunology* 2006; **177**(6): 3728-36.

28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis & rheumatism* 1997; **40**(9): 1725.

29. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. *Clinical and experimental immunology* 2010; **162**(2): 271-9.

30. Wang X, Jiang Y, Zhu Y, et al. Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis. *Journal of cellular and molecular medicine* 2016; **20**(5): 804-14.

31. Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. *Frontiers in immunology* 2015; **6**: 550.

32. Iwata S, Tanaka Y. B-cell subsets, signaling and their roles in secretion of autoantibodies. *Lupus* 2016; **25**(8): 850-6.

33. Jia XY, Zhu QQ, Wang YY, et al. The role and clinical significance of programmed cell death-ligand 1 expressed on CD19(+)-B-cells and subsets in systemic lupus erythematosus. *Clinical immunology* 2019; **198**: 89-99.

34. Scharer CD, Blalock EL, Mi T, et al. Epigenetic programming underpins B cell dysfunction in human SLE. *Nature immunology* 2019; **20**(8): 1071-82.

35. Jenks SA, Cashman KS, Zumaquero E, et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity* 2018; **49**(4): 725-39 e6.

36. Kubo S, Nakayamada S, Yoshikawa M, et al. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. *Arthritis & rheumatology* 2017; **69**(10): 2029-37.

37. Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. *Autoimmunity reviews* 2013; **12**(11): 1091-100.

38. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2006; **439**(7077): 682-7.

39. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* 2006; **443**(7109): 350-4.

40. Petrelli A, Mijnheer G, Hoytema van Konijnenburg DP, et al. PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. *The Journal of clinical investigation* 2018; **128**(10): 4669-81.

41. Caielli S, Veiga DT, Basilasubramanian P, et al. A CD4(+)- T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. *Nature medicine* 2019; **25**(1): 75-81.

42. Gordon SR, Maute RL, Duklen BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature* 2017; **545**(7655): 495-9.

43. Thibault ML, Mameessier E, Gertner-Dardenne J, et al. PD-1 is a novel regulator of human B-cell activation. *International immunology* 2013; **25**(2): 129-37.

44. McKay JT, Egan RP, Yammani RD, et al. PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. *Journal of immunology* 2015; **194**(5): 2289-99.

45. Okazaki T, Maeda A, Nishimura H, Kuosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. *Proceedings of the National Academy of Sciences of the United States of America* 2001; **98**(24): 13866-71.

#### Tables

| Table 1. Characteristics of SLE patients and healthy controls (mean ± SD, %). |  |
|---|---|
|  |
|  |  |
| Characteristic                        | SLE       | Control   | P value |
|-------------------------------------|-----------|-----------|---------|
| Cases                               | N = 74    | N = 54    |         |
| Number of males/females             | 3/71      | 3/51      | NS      |
| Age (year)                          | 31.42 ± 12.02 | 27.1 ± 8.1 | NS      |
| Disease duration (month)            | 49.13 ± 9.331 | -         | -       |
| Clinical features                   |           |           |         |
| SLEDAI≥10                           | 43        | -         |         |
| Lupus nephritis                     | 48        | -         |         |
| Raynaud’s phenomenon                | 27        | -         |         |
| Malar rash                          | 32        | -         |         |
| Fever                               | 47        | -         |         |
| Oral ulcer                          | 16        | -         |         |
| Arthritis                           | 35        | -         |         |
| Serositis                           | 32        | -         |         |
| Neurological disorder               | 18        | -         |         |
| Interstitial lung                   | 17        | -         |         |
| Laboratory findings                 |           |           |         |
| Anti-dsDNA(+)                       | 54        | -         |         |
| Anti-SmD1(+)                        | 60        | -         |         |
| Anti-U1snRNP(+)                     | 47        | -         |         |
| Anti-SSA60(+)                       | 55        | -         |         |
| Anti-SSA52(+)                       | 27        | -         |         |
| Anti-SSB(+)                         | 25        | -         |         |
| C3                                 | 78        | -         |         |
| C4                                 | 68        | -         |         |
| IgA                                 | 60        | -         |         |
| IgG                                 | 59        | -         |         |

Values are number (%) of patients unless indicate otherwise.
NS, No significance; SLE, systemic lupus erythematosus. SLEDAI, SLE Disease Activity Index; Anti-SmD1, Anti-Smith D1; Anti-dsDNA, Anti-double-stranded DNA; Anti-U1snRNP, Anti-U1 small nuclear ribonucleoprotein; Anti-SSA, Anti- Sjögren syndrome antigen A; Anti-SSB, Anti-Sjögren syndrome antigen B; C3/C4, complement component 3/4; IgG/IgM/IgA, immunoglobulin G/M/A.

Table 2. Correlation of the frequencies of PC, SM, NSM, DN and N B cells in SLE patients with SLEDAI or biochemical indices.

| Laboratory test parameters | SLEDAI | Amounts of proteinuria (g/24 h) | Immunoglobulin G (g/L) | Immunoglobulin A (g/L) | Immunoglobulin M (g/L) | Complement 3 (g/L) | Complement 4 (g/L) |
|----------------------------|--------|---------------------------------|------------------------|-----------------------|-----------------------|-------------------|-------------------|
| Cases                      | 74     | 0.03501                         | 0.08304*               | 0.01213               | 0.00436               | -0.0845*          |                   |
| PC B cells                 | 69     | -0.01255                        | 0.01846                | 0.09926*              | -0.02297              | -0.03198          |                   |
| SM B cells                 | 74     | 0.02445                         | 0.07461*               | 0.08158*              | 0.05188               | -0.2087*          |                   |
| NSM B cells                | 74     | 0.06296                         | 0.03587                | 0.1280                | -0.1827               | -0.04001          |                   |
| DN B cells                 | 74     | 0.09914*                        | -0.02337*              | -0.07387*             | 0.005707              | -0.02223          |                   |
| N B cells                  | 74     | 0.1162*                         | 0.006449               | 0.03364               | 0.001436              | -0.06764          |                   |

DN, double negative; naïve; NSM, non-switched memory; PC, plasmablast cells; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index; SM, switched memory.

*P < 0.05.

Table 3. Association between the percentages of PC, SM, NSM, DN and N B cells and the clinic-pathological parameters in SLE patients (mean ± SD, %).
| Parameters          | Cases  | B cells (%) | P value | SM M B cells (%) | P value | NSM B cells (%) | P value | DN M B cells (%) | P value | NB M B cells (%) | P value |
|---------------------|--------|-------------|---------|------------------|---------|-----------------|---------|------------------|---------|-----------------|---------|
| Anti-dsDNA +        | 44     | 0.300       | 0.896   | 0.641            | 0.084   | 0.198           |         |                  |         |                 |         |
|                     | - 30   | 0.138       | 0.007   | 0.420            | 0.017   | 0.388           | 3.409   | 50.35±           | 0.198   |                 |         |
| Anti-histones +     | 26     | 0.138       | 0.007   | 0.420            | 0.017   | 0.388           | 3.409   | 50.35±           | 0.198   |                 |         |
| Anti-smD1 +         | 45     | 0.193       | 0.522   | 0.702            | 0.537   | 0.225           | 1.644   | 4.82±           | 0.225   |                 |         |
|                     | - 29   | 0.193       | 0.522   | 0.702            | 0.537   | 0.225           | 1.644   | 4.82±           | 0.225   |                 |         |
| Anti-U1snRNP +      | 35     | 0.371       | 0.641   | 0.586            | 0.253   | 0.508           | 3.949   | 4.82±           | 0.225   |                 |         |
|                     | - 39   | 0.371       | 0.641   | 0.586            | 0.253   | 0.508           | 3.949   | 4.82±           | 0.225   |                 |         |
| Anti-nucleo +       | 35     | 0.571       | 0.326   | 0.277            | 0.108   | 0.704           | 3.949   | 4.82±           | 0.225   |                 |         |
|                     | - 39   | 0.571       | 0.326   | 0.277            | 0.108   | 0.704           | 3.949   | 4.82±           | 0.225   |                 |         |
| Anti-SSA60 +        | 41     | 0.832       | 0.062   | 0.424            | 0.173   | 0.049           | 1.319   | 3.81±           | 0.049   |                 |         |
|                     | - 33   | 0.832       | 0.062   | 0.424            | 0.173   | 0.049           | 1.319   | 3.81±           | 0.049   |                 |         |
| Anti-SSA52 +        | 20     | 0.856       | 0.022   | 0.02             | 0.167   | 0.013           | 1.267   | 3.68±           | 0.013   |                 |         |
|                     | - 54   | 0.856       | 0.022   | 0.02             | 0.167   | 0.013           | 1.267   | 3.68±           | 0.013   |                 |         |
| Anti-SSB +          | 15     | 0.761       | 0.530   | 0.019            | 0.587   | 0.145           | 4.939   | 2.99±           | 0.145   |                 |         |
|                     | - 59   | 0.761       | 0.530   | 0.019            | 0.587   | 0.145           | 4.939   | 2.99±           | 0.145   |                 |         |
| Anti-P0 +           | 30     | 0.605       | 0.108   | 0.103            | 0.334   | 0.210           | 3.65±   | 2.61±           | 0.013   |                 |         |
|                     | - 44   | 0.605       | 0.108   | 0.103            | 0.334   | 0.210           | 3.65±   | 2.61±           | 0.013   |                 |         |
| LN                  | Yes    | 0.299       | 0.761   | 0.250            | 0.889   | 0.525           | 4.939   | 2.99±           | 0.145   |                 |         |
| No                  | 38     | 0.299       | 0.761   | 0.250            | 0.889   | 0.525           | 4.939   | 2.99±           | 0.145   |                 |         |
| Malar rash          | Yes    | 0.011       | 0.001   | 0.957            | 0.807   | 0.013           | 4.35±   | 2.74±           | 0.013   |                 |         |
| No                  | 50     | 0.011       | 0.001   | 0.957            | 0.807   | 0.013           | 4.35±   | 2.74±           | 0.013   |                 |         |
| Arthritis           | Yes    | 0.322       | 0.529   | 0.597            | 0.261   | 0.093           | 1.319   | 3.81±           | 0.049   |                 |         |
| No                  | 48     | 0.322       | 0.529   | 0.597            | 0.261   | 0.093           | 1.319   | 3.81±           | 0.049   |                 |         |
| Serositis           | Yes    | 0.368       | 0.615   | 0.881            | 0.655   | 0.068           | 4.281   | 2.81±           | 0.068   |                 |         |
| No                  | 56     | 0.368       | 0.615   | 0.881            | 0.655   | 0.068           | 4.281   | 2.81±           | 0.068   |                 |         |
| Intestinal lung     | Yes    | 0.848       | 0.834   | 0.222            | 0.758   | 0.390           | 4.68±   | 2.74±           | 0.013   |                 |         |
| No                  | 61     | 0.848       | 0.834   | 0.222            | 0.758   | 0.390           | 4.68±   | 2.74±           | 0.013   |                 |         |

Table 4. Association between the percentage of PD-1+B cells and clinic-pathological parameters in SLE patients (mean ± SD, %).
### Table 5. Association between PD-1 expression on PC, SM, NSM, DN and N B cell subsets and the clinic-pathological parameters in SLE patients (mean ± SD, %).

| Parameters                  | Cases | PD-1⁺ B cells (%) | P*  |
|-----------------------------|-------|-------------------|-----|
| Anti-dsDNA                  | + 44  | 12.96±2.023       | 0.040 |
|                            | - 30  | 8.10±1.060        |     |
| Anti-histone                | + 26  | 15.03±2.454       | 0.025 |
|                            | - 48  | 10.22±0.798       |     |
| Anti-smD1                   | + 45  | 13.06±1.834       | 0.373 |
|                            | - 29  | 11.17±1.220       |     |
| Anti-U1snRNP                | + 35  | 12.53±1.617       | 0.571 |
|                            | - 39  | 11.35±1.326       |     |
| Anti-nucleo                 | + 35  | 12.21±1.397       | 0.766 |
|                            | - 39  | 11.59±1.540       |     |
| Anti-SSA60                  | + 41  | 12.82±1.459       | 0.234 |
|                            | - 33  | 10.23±1.128       |     |
| Anti-SSA52                  | + 20  | 15.25±2.829       | 0.048 |
|                            | - 54  | 10.67±0.9151      |     |
| Anti-SSB                    | + 15  | 13.47±2.930       | 0.451 |
|                            | - 59  | 11.52±1.066       |     |
| Anti-P0                     | + 30  | 11.03±1.294       | 0.486 |
|                            | - 44  | 12.51±1.498       |     |
| C3↓                         | Yes 58| 12.21±1.475       | 0.881 |
|                            | No 16 | 11.83±1.256       |     |
| IgG↑                        | Yes 44| 12.52±1.686       | 0.621 |
|                            | No 30 | 11.47±1.305       |     |
| Lupus nephritis             | Yes 36| 15.55±1.912       | <0.0001 |
|                            | No 38 | 8.46±0.386        |     |
| Malar rash                  | Yes 24| 14.08±2.459       | 0.146 |
|                            | No 50 | 10.87±0.956       |     |
| Fever                       | Yes 35| 12.14±1.584       | 0.838 |
|                            | No 39 | 11.71±1.363       |     |
| Oral ulcer                  | Yes 12| 16.49±3.818       | 0.049 |
|                            | No 62 | 11.02±0.964       |     |
| Arthritis                   | Yes 26| 12.10±1.937       | 0.895 |
|                            | No 48 | 11.81±1.210       |     |
| Serositis                   | Yes 18| 9.87±1.491        | 0.265 |
|                            | No 56 | 12.57±9.501       |     |
| Interstitial lung           | Yes 13| 9.50±1.869        | 0.283 |
|                            | No 61 | 12.42±1.181       |     |

Anti-SmD1, anti-Smith D1, Anti-dsDNA, Anti-double-stranded DNA; Anti-U1snRNP, Anti-U1 small nuclear ribonucleoprotein; Anti-nucleo, Anti-nucleosomes, Anti-SSA, Anti-Sjögren syndrome antigen A; Anti-SSB, Anti-Sjögren syndrome antigen B, Anti-P0, anti-ribosomal P0 antibody, C3 complement component 3; IgG, immunoglobulin G; SLE, systemic lupus erythematosus.
### Figures

**Figures**

**Table 1:** Summary of the antigens and antibodies investigated in the study.

| Parameters               | Cases | IgG, immunoglobulin G; Anti-ribosomal P0 antibody, C3, complement component 3; DN, double negative; IgG, immunoglobulin G; LN, lupus nephritis; N, naive; NSM, non-switched memory; PC, plasmablast cells; SLE, systemic lupus erythematosus; SM, switched memory. | Anti-SmDNA | Anti-SmDNA | Anti-SmDNA | Anti-SmDNA | Anti-SmDNA | Anti-SmDNA | Anti-SmDNA | Anti-SmDNA |
|-------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Anti-dsDNA              | -20   | 4.873±0.373                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Anti-smD1               | 35    | 6.227±1.105                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Anti-nucleo             | 35    | 6.397±1.044                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Anti-SSA60              | 41    | 6.807±1.100                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Anti-SSA52              | 20    | 8.752±2.518                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Anti-SSB                | 15    | 8.457±2.422                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Anti-P0                 | 30    | 5.945±0.458                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| C3                      | Yes   | 1.256±0.910                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| IgG                     | Yes   | 6.414±0.890                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| LN                      | Yes   | 7.557±1.424                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Malar rash              | 24    | 7.344±2.100                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Oral ulcer              | 12    | 7.816±3.071                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Arthritis               | 26    | 6.233±1.449                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Serositis               | 18    | 4.698±0.675                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |
| Intestinal lymphoma     | 13    | 4.205±0.726                                                                                                                    | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       | 0.001       |

*Note: It is important to include the full context and explanation for each parameter and its significance within the study. Additionally, it is crucial to ensure that all antigens and antibodies are properly identified and defined.*
Figure 1

The proportion of B cell subsets is aberrant in SLE patients. (A) Representative dot plots from one patient and one control sample indicating the gating strategy for CD19+ B cells. (B) Percentage of CD19+ B cells in the controls and patients with inactive (SLEDAI <10) and active (SLEDAI ≥10) SLE. ***P < 0.00001 (one-way analysis of variance). (C) Representative dot plots from one patient and one control sample indicating the distribution of B-cell subsets in the peripheral blood. PC - plasmablast cells (CD27high IgD-); SM - switched memory (CD27+ IgD-); NSM - non-switched memory (CD27+ IgD+); DN - double negative (CD19+ IgD- CD27-); N - Naïve (CD27- IgD+). (D) Proportion of B-cell subsets in controls and patients (x ± s, %); *P<0.05 (Student t test). (E) Correlation of CD19+ B cell frequency with SLEDAI (SLE Disease Activity Index) scores, proteinuria and C3 levels. All data were expressed as mean ± standard deviation.
Figure 2

PD-1+ is differentially expressed on the B cells from SLE patients and controls. (A) Representative dot plots from one patient and one control sample indicating the gating strategy for CD19+ PD-1+ B cells. (B) Percentage of PD-1+ B cells in the controls and patients with inactive (SLEDIA <10) and active (SLEDIA ≥10) SLE. ***P < 0.0001 (one-way analysis of variance). (C) Representative dot plots from one patient and one control sample indicating the gating strategy for PD-1+ PC, SM, NSM, DN and N subsets. (D) Percentage of PD-1+ B-cell subsets in controls and patients. **P <0.001, ***P <0.0001 (mean ± SD, %; Student t test). (E) Correlation of CD19+ PD-1+ B cell frequency with SLEDAI (SLE Disease Activity Index) scores, proteinuria and C3 levels. All data were expressed as mean ± standard deviation. (F) Correlation of CD19+ PD-1+ B cell subsets with SLEDAI (SLE Disease Activity Index) scores, proteinuria and C3 levels. All data were expressed as mean ± standard deviation.

Figure 3

Proliferation of PD-1+ or PD-1− B cells in response to CpG DNA stimulation. (A) Proliferation of B cells in the presence of CpG DNA and/or anti-IgM antibody. (B) Proliferation rates of SLE/control PD-1+ and PD-1− B cells at days 1, 2, 3 and 7 of CpG DNA stimulation. (C-D) The levels of (C) anti-dsDNA antibodies and
(D) IgG secreted by the control PD-1+, SLE PD-1+, control PD-1+ and SLE PD-1+ B cells at days 1, 2, 3 and 7 of CpG DNA stimulation. All data were expressed as mean ± standard deviation. *P < .05, **P < .01, ***P < .001. One-way analysis of variance followed by a Newman–Keuls post hoc test.